Details of the Drug

General Information of Drug (ID: DM9HQ5U)

Drug Name
Tagraxofusp
Synonyms Tagraxofusp [INN]; Molecule 129; Tagraxofusp [USAN]; UNII-8ZHS5657EH; 8ZHS5657EH; Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
Indication
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Approved [1]
Blastic plasmacytoid dendritic cell neoplasm 2A60.5 Approved [1]
Sequence
MGADDVVDSSKSFVMENFSSYHGTKPGYVDSIQKGIQKPKSGTQGNYDDDWKGFYSTDNK
YDAAGYSVDNENPLSGKAGGVVKVTYPGLTKVLALKVDNAETIKKELGLSLTEPLMEQVG
TEEFIKRFGDGASRVVLSLPFAEGSSSVEYINNWEQAKALSVELEINFETRGKRGQDAMY
EYMAQACAGNRVRRSVGSSLSCINLDWDVIRDKTKTKIESLKEHGPIKNKMSESPNKTVS
EEKAKQYLEEFHQTALEHPELSELKTVTGTNPVFAGANYAAWAVNVAQVIDSETADNLEK
TTAALSILPGIGSVMGIADGAVHHNTEEIVAQSIALSSLMVAQAIPLVGELVDIGFAAYN
FVESIINLFQVVHNSYNRPAYSPGHKTRPHMAPMTQTTSLKTSWVNCSNMIDEIITHLKQ
PPLPLLDFNNLNGEDQDILMENNLRRPNLEAFNRAVKSLQNASAIESILKNLLPCLPLAT
AAPTRHPIHIKDGDWNEFRRKLTFYLKTLENAQAQQTTLSLAIF
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 231 mcgh/L [2]
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 162 mcg/L [2]
Clearance
The clearance of drug is 7.1 L/h [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 51 minutes [2]
Metabolism
The drug is metabolized via proteases []
Vd
The volume of distribution (Vd) of drug is 5.1 L []
Cross-matching ID
DrugBank ID
DB14731
TTD ID
D0R7NI

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin 3 receptor alpha (IL3RA) TTENHJ0 IL3RA_HUMAN Modulator [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Acute myeloid leukaemia
ICD Disease Classification 2A60
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin 3 receptor alpha (IL3RA) DTT IL3RA 8.71E-54 0.98 2.64
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Tagraxofusp (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Tagraxofusp and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [3]

References

1 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
2 Blood journal
3 Cerner Multum, Inc. "Australian Product Information.".